Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis

Cancer Cell International

Takashi Murakami¹  Kentaro Takahashi¹  Nobuyuki Kita¹  Akie Takebayashi¹  Akiyoshi Yamanaka¹  Fuminori Kimura¹  Akimasa Takahashi¹ 

[1] Department of Obstetrics and Gynecology, Shiga University of Medical Science, Seta-Tsukinowa-cho, Otsu, Shiga 520-2192, Japan

关键词: Apoptosis;    Autophagy;    Endometrial cancer;    Metformin;   

Others  :  791814
DOI  :  10.1186/1475-2867-14-53

 received in 2014-03-17, accepted in 2014-06-11,  发布年份 2014

【 摘 要 】

Background

Effective therapies for early endometrial cancer usually involve surgical excision and consequent infertility Therefore, new treatment approaches that preserve fertility should be developed. Metformin, a well-tolerated anti-diabetic drug, can inhibit cancer cell growth. However, the mechanism of metformin action is not well understood. Here we investigate the roles of autophagy and apoptosis in the anti-cancer effects of metformin on endometrial cancer cells.

Methods

Ishikawa endometrial cancer cells were treated with metformin. WST-8 assays, colony formation assays, flow cytometry, caspase luminescence measurement, immunofluorescence, and western blots were used to assess the effects of metformin on cell viability, proliferation, cell cycle progression, apoptosis, and autophagy.

Results

Metformin-treated cells exhibited significantly lower viability and proliferation and significantly more cell cycle arrest in G1 and G2/M than control cells. These cells also exhibited significantly more apoptosis via both intrinsic and extrinsic pathways. In addition, metformin treatment induced autophagy. Inhibition of autophagy, either by Beclin1 knockdown or by 3-methyladenine-mediated inhibition of caspase-3/7, suppressed the anti-proliferative effects of metformin on endometrial cancer cells. These findings indicate that the anti-proliferative effects and apoptosis caused by metformin are partially or completely dependent on autophagy.

Conclusions

We showed that metformin suppresses endometrial cancer cell growth via cell cycle arrest and concomitant autophagy and apoptosis.

【 授权许可】

   
2014 Takahashi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
• [2]Ushijima K: Current status of gynecologic cancer in Japan. J Gynecol Oncol 2009, 20(2):67-71.
• [3]Rose PG: Endometrial carcinoma. N Engl J Med 1996, 335(9):640-649.
• [4]Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I: Endometrial cancer. Lancet 2005, 366(9484):491-505.
• [5]Crissman JD, Azoury RS, Barnes AE, Schellhas HF: Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 1981, 57(6):699-704.
• [6]Gallup DG, Stock RJ: Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984, 64(3):417-420.
• [7]Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF: Endometrial cancer in women 40 years old or younger. Gynecol Oncol 2001, 83(2):388-393.
• [8]Ota T, Yoshida M, Kimura M, Kinoshita K: Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 2005, 15(4):657-662.
• [9]Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM: Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988, 158(4):796-807.
• [10]Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH: Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005, 105(3):575-580.
• [11]Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F: Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012, 122(6):253-270.
• [12]Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007, 67(14):6745-6752.
• [13]Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008, 110(2):246-250.
• [14]Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM: Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 2008, 14(47):7192-7198.
• [15]Zhuang Y, Miskimins WK: Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008, 3:18.
• [16]Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8(6):909-915.
• [17]Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, Tartare-Deckert S, Bahadoran P, Auberger P, Ballotti R, Rocchi S: Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2011, 2:e199.
• [18]Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y, Zhao WL: Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis 2012, 3:e275.
• [19]Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation–implications for a novel treatment strategy. Gynecol Oncol 2010, 116(1):92-98.
• [20]Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA, Bae-Jump VL: Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol 2012, 125(2):458-469.
• [21]Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A: Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009, 16(7):966-975.
• [22]Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E: Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 2005, 1(2):84-91.
• [23]Jing K, Song KS, Shin S, Kim N, Jeong S, Oh HR, Park JH, Seo KS, Heo JY, Han J, Park JI, Han C, Wu T, Kweon GR, Park SK, Yoon WH, Hwang BD, Lim K: Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. Autophagy 2011, 7(11):1348-1358.
• [24]Wang N, Pan W, Zhu M, Zhang M, Hao X, Liang G, Feng Y: Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells. Br J Pharmacol 2011, 164(2b):731-742.
• [25]Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009, 8(13):2031-2040.
• [26]Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D, Yahalom J: A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001, 61(2):439-444.
• [27]Luo Q, Hu D, Hu S, Yan M, Sun Z, Chen F: In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer 2012, 12:517.
• [28]Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, Kobara H, Mori H, Himoto T, Okano K, Suzuki Y, Murao K, Masaki T: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012, 11(3):549-560.
• [29]Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, Liao QP: Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011, 126(3–5):113-120.
• [30]Zhang Z, Dong L, Sui L, Yang Y, Liu X, Yu Y, Zhu Y, Feng Y: Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer 2011, 21(2):213-221.
• [31]Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F: Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010, 9(5):1092-1099.
• [32]Rattan R, Giri S, Hartmann LC, Shridhar V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 2011, 15(1):166-178.
• [33]Vermeulen K, Van Bockstaele DR, Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003, 36(3):131-149.
• [34]Kawabe T: G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004, 3(4):513-519.
• [35]Murai Y, Hayashi S, Takahashi H, Tsuneyama K, Takano Y: Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines. Pathol Res Pract 2005, 201(2):109-115.
• [36]Ahn MY, Jung JH, Na YJ, Kim HS: A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 2008, 108(1):27-33.
• [37]Mizushima N, Levine B, Cuervo AM, Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature 2008, 451(7182):1069-1075.
• [38]Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB: Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007, 117(2):326-336.
• [39]Műzes G, Sipos F: Anti-tumor immunity, autophagy and chemotherapy. World J Gastroenterol 2012, 18(45):6537-6540.
• [40]Maiuri MC, Zalckvar E, Kimchi A, Kroemer G: Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007, 8(9):741-752.